RECRUITING Early Phase 1 ClinicalTrials.gov

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • ClinicalTrials.gov ID: NCT06959979

Registry updated: 2026-09-03

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.

Interventions

CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib) (Drug)
Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).

Eligibility criteria

Inclusion Criteria: * All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study

Conditions

Medulloblastoma, Childhood

Locations

Fondazione Policlinico Gemelli Irccs — Roma, ROMA, Italy

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment